%0 Editorial
%T The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity.
%A Kowalski DM
%A Zaborowska-Szmit M
%A Szmit S
%A Jaśkiewicz P
%A Krzakowski M
%J Transl Lung Cancer Res
%V 13
%N 6
%D 2024 Jun 30
%M 38973950
%F 4.726
%R 10.21037/tlcr-24-204